Acute disseminated encephalomyelitis: Difference between revisions

	Multiple sclerosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple sclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Alternative Therapies
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute disseminated encephalomyelitis On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute disseminated encephalomyelitis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute disseminated encephalomyelitis
CDC on Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis in the news
Blogs on Acute disseminated encephalomyelitis
Directions to Hospitals Treating Multiple sclerosis
Risk calculators and risk factors for Acute disseminated encephalomyelitis

	Acute disseminated encephalomyelitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute disseminated encephalomyelitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute disseminated encephalomyelitis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute disseminated encephalomyelitis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute disseminated encephalomyelitis
CDC on Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis in the news
Blogs on Acute disseminated encephalomyelitis
Directions to Hospitals Treating Acute disseminated encephalomyelitis
Risk calculators and risk factors for Acute disseminated encephalomyelitis

	Acute disseminated encephalomyelitis;
ICD-10	G04.0
ICD-9	323.61
DiseasesDB	158
MeSH	D004673

Revision as of 20:44, 20 November 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: ADEM

There are case reports of improvement with treatment with plasma exhange and intravenous immunoglobulin in patients who have not responded to steroids.
The first treatment is usually steroids and intensive care is often required.

Most patients are treated with pulse intravenous methylprednisolone with subsequent taper.

The content on this page was first contributed by: ELLISON L. SMITH, M.D.

@@ Line 17: / Line 17: @@
 {{SK}} ADEM
-== Risk Stratification and Prognosis==
-* Prognosis varies with the severity of the neurologic disease.  Some patients will not survive the acute illness, and some will be left with neurologic sequelae.  Some remarkably recover completely.
-* The disease is characteristically monophasic, but descriptions of multiphasic disease have been reported.
-* Affected children will often suffer from persistent seizures and behavioral and learning disorders.  Adults are somewhat less likely than children to have neurologic sequelae.
 == Treatment ==

Acute disseminated encephalomyelitis
ICD-10	G04.0
ICD-9	323.61
DiseasesDB	158
MeSH	D004673